Celcuity (CELC) traded lower Friday, down roughly 3%, in a move that appears largely technical rather than headline-driven. Celcuity’s investor-relations feed shows no new press releases in April 2026, leaving investors to trade the stock around previously disclosed milestones and near-term positioning after a strong run into late March. (ir.celcuity.com)

Celcuity’s March 25, 2026 corporate update highlighted two key upcoming inflection points: an FDA Priority Review for gedatolisib with a July 17, 2026 PDUFA goal date, and expected topline results in Q2 2026 from the PIK3CA-mutant cohort of the Phase 3 VIKTORIA-1 study. When a stock is priced for catalyst success, modest pullbacks can occur on light news as traders reduce exposure or rebalance risk ahead of binary events. (ir.celcuity.com)

After a catalyst-driven rally, biotech names frequently see profit-taking and hedging as the market approaches defined dates, especially when the next update is still weeks away. With the PDUFA date (July 17, 2026) and the still-to-be-timed Q2 data release in focus, Friday’s dip looks consistent with investors trimming into strength rather than reacting to a new fundamental setback. (ir.celcuity.com)

Near-term, investors will be watching for any FDA review updates, commercial-launch preparations tied to potential approval timing, and the exact timing of the VIKTORIA-1 PIK3CA-mutant cohort topline release that Celcuity has guided for Q2 2026. Any change to timing, labeling expectations, or safety/efficacy framing could quickly shift sentiment given how much of the valuation is tied to gedatolisib’s path to market. (ir.celcuity.com)